Skip to content
To the full analysis

Sarepta Therapeutics stock: balance sheet and debt

SRPT
$16.01Closing price of 12 Nov 2026MEQIRI Score 39 out of 100

Sarepta Therapeutics has a debt to equity ratio of 0.91.

Daily figure as of 13 Nov 2026

Debt / Equity
0.91
Interest coverage
−50x
Current ratio
2.32
Cash & equivalents
$939.65M
Total assets
$3.35B
Equity ratio
34.1%
Goodwill and intangible assets
$28.95M
not split out
Net debt
$100.1M

Total assets and equity ratio

How large the balance sheet of Sarepta Therapeutics, Inc. is, how much of it is equity and how much is goodwill from acquisitions.

Equity ratio

Figures as a table
YearTotal assetsGoodwill and intangible assetsof which goodwillEquity ratioNet debt
2006$40.86M$2.56Mnot split out92.3%−$33.15M
2007$38.64M$3.07Mnot split out68.3%−$22.93M
2008$25.54M$3.27Mnot split out61.6%−$9.4M
2009$60.03M$3.76Mnot split out39.4%−$46.45M
2010$45.98M$3.98Mnot split out−6.1%−$31.67M
2011$54.37M$4.76Mnot split out57.1%−$38.06M
2012$204.99M$4.91Mnot split out60.3%−$185.9M
2013$291.57M$5.04Mnot split out84.8%−$255.3M
2014$295.03M$5.89Mnot split out83.9%−$204.02M
2015$273.78M$6.64Mnot split out69.5%−$169.09M
2016$424.1M$8.08Mnot split out79.4%−$301.7M
2017$1.31B$14.36Mnot split out60.3%−$648.01M
2018$1.64B$11.57Mnot split out62.9%−$753.36M
2019$1.82B$12.5Mnot split out44.9%−$387.28M
2020$2.98B$13.63Mnot split out25.5%−$844.78M
2021$3.15B$14.24Mnot split out29.5%−$962.43M
2022$3.13B$7.58Mnot split out12.3%−$372.02M
2023$3.26B$29.62Mnot split out26.3%−$279.44M
2024$3.96B$26.89Mnot split out38.5%−$11.72M
2025$3.35B$28.95Mnot split out34.1%$100.1M

The equity ratio divides total equity, including non-controlling interests, by total assets. Net debt is debt minus cash and short-term investments; a negative figure means cash exceeds debt. In years without separate goodwill, the table shows the sum of goodwill and intangible assets, because the data do not list goodwill separately there.

Equity and debt

What the company owns and owes

  • Cash & equivalents
  • Equity
  • Debt
Figures as a table
YearCash & equivalentsEquityDebtDebt / Equity
2006$33.15M$37.71M$00
2007$25.07M$26.38M$2.14M0.08
2008$11.47M$15.73M$2.07M0.13
2009$48.45M$23.63M$2M0.08
2010$33.59M−$2.82M$1.92M−0.68
2011$39.9M$31.02M$1.84M0.06
2012$187.66M$123.68M$1.76M0.01
2013$256.97M$247.19M$1.67M0.01
2014$210.34M$247.65M$6.33M0.03
2015$192.49M$190.35M$23.4M0.12
2016$317.85M$336.69M$16.15M0.05
2017$1.08B$789.22M$431.05M0.55
2018$1.17B$1.03B$420.55M0.41
2019$1.12B$818.19M$737.47M0.9
2020$1.94B$761.76M$1.09B1.44
2021$2.12B$928.01M$1.15B1.24
2022$1.99B$384.95M$1.62B4.2
2023$1.68B$859.34M$1.4B1.63
2024$1.35B$1.53B$1.34B0.88
2025$939.65M$1.14B$1.04B0.91

Data status and sources

Score
Daily value of 13 Nov 2026, recalculated nightly
Price
Closing price of 12 Nov 2026
Latest annual report
Fiscal year 2025, period end 31 Dec 2025
Source
Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.

Mandatory disclosures for this rating

  • ; time horizon around 12 months
  • Rated Weak, published since 7 Nov 2026 (in the score history since 9 May 2025)
  • Valuation signal Fairly valued since 7 Nov 2026
  • End-of-day prices, metrics cached for up to 24 hours
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.

MEQIRI counts visits without cookies. With your consent we remember for 90 days where you came from, also in your account, count page changes and time on page, recognise your next visit and load the Meta Pixel, which measures our advertising. You can withdraw your consent at any time under Cookie settings. Privacy